Net income increased to $24.6 million in 2025 from $6.7 million in 2024, primarily due to a $21.2 million income tax benefit from the partial release of a valuation allowance. Consolidated revenue decreased by 18% to $38.7 million in 2025, down from $46.9 million in 2024, mainly driven by the loss of reimbursement for the PancraGEN test. The company discontinued its PancraGEN test after the Center for Medicare and Medicaid Services (CMS) ceased reimbursement coverage on April 24, 2025, and stopped accepting specimens after May 2, 2025. Current efforts are concentrated on molecular diagnostic tests for thyroid cancer, ThyGeNEXT and ThyraMIRv2. Operating income from continuing operations decreased to $4.1 million in 2025 from $8.1 million in 2024. Gross profit decreased by 19% to $24.1 million in 2025, compared to $29.9 million in 2024. A restructuring plan was implemented in April 2025, resulting in a workforce reduction and $0.7 million in severance and related costs. Cash and cash equivalents were $2.5 million as of December 31, 2025, and approximately $2.4 million as of March 20, 2026. All Series C Preferred Stock was converted into approximately 23,267,327 shares of common stock on January 20, 2026. Ampersand and 1315 Capital, two private equity firms, collectively control 84% of the company's outstanding common stock (50% and 34% respectively). The company's common stock was delisted from Nasdaq in February 2021, removed from OTCQX on August 18, 2025, and now trades on the OTCID tier. A material weakness in internal control over financial reporting related to the review of complex agreements was remediated by December 31, 2025.